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Abstract
 
Apoptosis is a key for CD4
 
1
 
 T cell destruction in HIV-1–infected patients. In this study, hu-
man peripheral blood lymphocyte (PBL)-transplanted nonobese diabetic (NOD)-severe com-
bined immunodeficient (SCID) (hu-PBL-NOD-SCID) mice were used to examine in vivo
apoptosis after HIV-1 infection. As the hu-PBL-NOD-SCID mouse model allowed us to see
extensive infection with HIV-1 and to analyze apoptosis in human cells in combination with
immunohistological methods, we were able to quantify the number of apoptotic cells with
HIV-1 infection. As demonstrated by terminal deoxynucleotidyl transferase–mediated dUTP
nick-end labeling (TUNEL), massive apoptosis was predominantly observed in virus-unin-
fected CD4
 
1
 
 T cells in the spleens of HIV-1–infected mice. A combination of TUNEL and
immunostaining for death-inducing tumor necrosis factor (TNF) family molecules indicated
that the apoptotic cells were frequently found in conjugation with TNF-related apoptosis-
inducing ligand (TRAIL)-expressing CD3
 
1
 
CD4
 
1
 
 human T cells. Administration of a neutral-
izing anti-TRAIL mAb in HIV-1–infected mice markedly inhibited the development of
CD4
 
1
 
 T cell apoptosis. These results suggest that a large number of HIV-1–uninfected CD4
 
1
 
T cells undergo TRAIL-mediated apoptosis in HIV-infected lymphoid organs.
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Introduction
 
HIV infection induces gradual loss of CD4
 
1
 
 T cells, leading
to AIDS, but the mechanism of this cell loss remains un-
clear. Severe impairment of T cell development (1) and in-
creased destruction of CD4
 
1
 
 T cells in secondary lymphoid
organs such as lymph nodes and spleens have been reported
in HIV-infected individuals (2). Histopathological analyses
of HIV-1– or simian immunodeficiency virus (SIV)-infected
lymph nodes showed that apoptosis occurs mostly in virus-
uninfected bystander CD4
 
1
 
 T cells (3). The role of ap-
optosis in the CD4
 
1
 
 T cell loss has also been suggested by
the following in vitro experiments: (a) a greater proportion
of peripheral blood T cells from HIV-1–infected individuals
became apoptotic in culture after TCR-mediated activation
(activation-induced cell death [AICD]) (4, 5); and (b) the
proportion of Fas-expressing T cells in HIV-1–infected in-
dividuals increased with disease progression, and ligation of
Fas with specific Abs induced apoptosis of T cells in vitro
(6, 7). However, possible involvement of the Fas–Fas ligand
 
(FasL) pathway in AICD of CD4
 
1
 
 T cells from HIV-1–
infected individuals (8, 9) remains controversial. Another
report has indicated that AICD was independent of Fas
(10), and it has been shown that neither Fas protein nor bi-
ologically active FasL were detectable at significant levels in
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freshly isolated T cells from HIV-1–infected individuals
(11). These results strongly suggested the involvement of
other mechanisms in the apoptosis of CD4
 
1
 
 T cells in HIV-
infected individuals.
TNF-related apoptosis-inducing ligand (TRAIL)/Apo-
2L is a new member of death-inducing ligands in the TNF
family (12). While it has been reported that TRAIL in-
duced apoptosis in various tumor cells in vivo, pathophysi-
ological roles of TRAIL are largely unknown. It has been
shown that TRAIL was expressed in IFN-
 
a
 
–stimulated
CD4
 
1
 
 T cells (13), monocytes (14), and dendritic cells
(DCs) (15). In addition, it was recently reported that infec-
tion with measles virus augmented TRAIL expression in
DCs (16). Therefore, it is possible that TRAIL may be in-
volved in HIV pathologies. In fact, it has been reported
that TRAIL, but not FasL, was involved in AICD of
CD4
 
1
 
 T cells isolated from HIV-1–infected individuals in
vitro
 
 
 
(17, 18).
Lymphoid organs are thought to be the major site of
HIV replication and pathogenesis (19, 20). To explore the
immunopathological processes occurring in these organs in
HIV-infected humans, it is helpful to develop an appropri-
ate animal model. We have previously shown that the non-
obese diabetic (NOD)-SCID mouse is a useful strain for
both successful engraftment of human PBLs and massive
HIV-1 replication, probably due to its severe immunodefi-
ciency, including innate immunity (21). In this model, en-
grafted human cells migrated to various organs, including
the spleen, and human CD4
 
1
 
 T cells were efficiently killed
by HIV-1 injection. In this study, we found that this model
is useful for analysis of apoptotic cells and that TRAIL
played a critical role in inducing the apoptosis of HIV-1–
uninfected human CD4
 
1
 
 T cells. The possible clinical rele-
vance of this finding is discussed.
 
Materials and Methods
 
Mice.
 
NOD (NOD/Shi) 
 
scid/scid
 
 mice (21) were maintained
in the Central Institute for Experimental Animals (Kawasaki, Ja-
pan). The mice were screened for immunodeficiency by immu-
nodiffusion assay (Medical and Biological Laboratory, Nagoya,
Japan) for serum IgM and were 6–8 wk old at the time of human
PBMC transfer. The experimental protocol was approved by the
Ethics Review Committees for Animal Experimentation of the
participating institutions.
 
Reconstitution and HIV-1 Infection of hu-PBL-NOD-SCID
Mice.
 
Reconstitution with human PBLs and infection with
HIV-1 were performed as previously described (21, 22). 1,000
ID
 
50
 
 of HIV-1 was inoculated intraperitoneally. Cloned HIV-1
isolates, including macrophage-tropic viruses JR-FL or green flu-
orescent protein (GFP)-carrying HIV-1 (data not shown), were
employed. Mice were killed 2–4 wk after infection. 1 mg of anti–
human TRAIL mAb (RIK-2) (23), anti–human FasL mAb
(NOK-1) (24), or control mouse IgG (Inter-Cell Technologies,
Inc.) was injected intraperitoneally 9 d after HIV-1
 
JR-FL
 
 infection.
These mice were killed 3 d later, and the spleens were collected.
 
Histological Analyses.
 
Mouse spleen was fixed in 4% perio-
date-lysine-paraformaldehyde fixative (25, 26), embedded in ei-
ther paraffin or Tissue-Tek OCT compound and cut into 6- or
10-
 
m
 
m-thick sections. Paraffin sections were dried, dewaxed in
 
xylene, ethanol, and water, and then stained with hematoxylin
and eosin. The paraffin sections were initially either treated with
0.0025% trypsin solution for human CD68 detection or micro-
waved for human CD8 and HIV-1 p24
 
gag
 
 detection. Both treat-
ments were required for human CD3 and CD4 detection. Tissue
sections were incubated with primary Abs against human CD3
(rabbit polyclonal IgG; Dako), human CD4 (clone 1F6, mouse
IgG; NeoMarkers), human CD8 (clone C8/144B, mouse IgG;
Dako), human CD68 (clone PGM1, mouse IgG; Dako), human
CD20 (clone L26, mouse IgG; Dako), or HIV-1 p24
 
gag
 
 (clone
Kal-1, mouse IgG; Dako). Subsequently, the avidin-biotinylated
peroxidase complex (ABC) method (Vector Laboratories) for hu-
man CD4 staining, the enhanced polymer one-step staining
(EPOS) method (Dako) for human CD68 and CD20 staining, the
EnVision™
 
1
 
 method (Dako) for human CD3 and CD8 staining,
or the TSA™-Indirect method (NEN Life Science Products) for
HIV-1 p24
 
gag
 
 staining was performed as described previously (27,
28). Nonimmunized mouse IgG (Inter-Cell Technologies, Inc.)
or rabbit IgG (Dako) was used as a negative control.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP
nick-end labeling (TUNEL) was carried out using an indirect
method according to the instructions provided by the manufac-
turer. Frozen sections were incubated with TdT reaction solution
(0.02 
 
m
 
g/
 
m
 
l digoxigenin-labeled dUTP, 0.012 U/
 
m
 
l TdT;
Roche), followed by tetramethylrhodamine isothiocyanate
(TRITC)-conjugated antidigoxigenin Ab (Roche). The specific-
ity of the TUNEL staining was confirmed by the following: (a)
absence of either digoxigenin-labeled dUTP or TdT served as a
negative control; (b) DNase-treated section as a positive control
showed positive staining in all nuclei.
Combinations of TUNEL and immunostaining using specific
Abs were performed as follows. The first combination was for
human CD4, TUNEL, and HIV p24
 
gag
 
. Labeled streptavidin bi-
otin (LSAB) technique with Cy5 (Amersham Pharmacia Biotech)
was performed using anti–human CD4 mAb (clone MT310,
mouse IgG; Dako). TSA™-Direct method was performed for
TUNEL using horseradish peroxidase (HRP)-conjugated anti-
digoxigenin Ab (sheep IgG Fab fragment; Roche) and TRITC-
conjugated tyramide (NEN Life Science Products). Final staining
was carried out with FITC-conjugated anti-HIV p24
 
gag
 
 mAb
(Verostat Inc.) enhanced with anti-FITC Ab (rabbit polyclonal
IgG; Molecular Probes, Inc.) and FITC-conjugated goat anti–
rabbit IgG Ab (Zymed Laboratories). Biotinylated horse anti–
mouse IgG Ab (Vector Laboratories), which was the secondary
Ab for human CD4, did not react with rabbit and sheep IgG. To
block the unoccupied binding sites of this secondary Ab, sections
were incubated with nonimmunized mouse IgG (Inter-Cell
Technologies, Inc.) and nonimmunized goat serum (Vector Lab-
oratories) before incubation of anti-HIV p24
 
gag
 
 mAb. FITC-con-
jugated anti–rabbit IgG Ab, which was used as the third-step Ab
for p24
 
gag
 
, had been absorbed with mouse and horse serum. To
block the unoccupied binding sites, sections were incubated with
a sheep IgG Fab fragment (Rockland Inc.).
The second combination was for TRAIL and TUNEL. Cy5-
LSAB method was performed with anti-TRAIL Ab (K-18, goat
polyclonal IgG; Santa Cruz Biotechnology, Inc.). An indirect
method was used with TRITC-conjugated antidigoxigenin Ab
for TUNEL. Biotinylated donkey anti–goat IgG Ab (Poly-
sciences, Inc.), which was used as the secondary Ab, had been ab-
sorbed with sheep serum.
The third combination was for human Fas, FasL, and TUNEL.
Cy5-LSAB method was performed using anti–human Fas mAb
(clone APO-1, mouse IgG; Dako), and an indirect method was 
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performed with FITC-conjugated anti–rabbit IgG Ab for anti-
FasL Ab (C-20, rabbit polyclonal IgG; Santa Cruz Biotechnology,
Inc.). To block the unoccupied binding sites of biotinylated anti–
mouse IgG Ab, sections were incubated with nonimmunized goat
serum before FITC-conjugated anti–rabbit IgG Ab incubation.
The fourth combination was for human TNF-
 
a
 
, TNFR1, and
TUNEL. Cy5-LSAB method was performed with anti-TNFR1
Ab (C-20, goat polyclonal IgG; Santa Cruz Biotechnology, Inc.).
TSA™-Direct method was performed with anti-TNF-
 
a
 
 mAb
(clone C6-H6, mouse IgG; NeoMarkers), FITC-conjugated
horse anti–mouse IgG Ab (Vector laboratories), HRP-conjugated
goat anti-FITC Ab (NEN Life Science Products), and FITC-
conjugated tyramide (NEN Life Science Products). To block the
unoccupied binding sites of biotinylated anti–goat IgG Ab, sec-
tions were incubated with nonimmunized goat serum before
HRP-conjugated anti-FITC Ab incubation.
The fifth combination was for human CD4, TRAIL, and
TUNEL. Cy5-LSAB method was performed with anti-TRAIL
Ab. An indirect method was performed using anti–human CD4
mAb (clone MT310) and FITC-conjugated donkey anti–mouse
IgG Ab (Chemicon International Inc.). TUNEL was carried out
by the indirect method as above. Biotinylated anti–goat IgG Ab
(Polysciences, Inc.), which was used as the secondary Ab for
TRAIL, had been absorbed with mouse and sheep serum. FITC-
conjugated donkey anti-mouse IgG Ab, which was used as the sec-
ondary Ab for human CD4, did not react with goat and sheep IgG.
The sixth combination was for human CD3, TRAIL, and
TUNEL. Immunostaining for TRAIL and TUNEL was carried
out as in the fifth combination. Subsequently, an indirect method
using anti–human CD3 Ab (rabbit polyclonal IgG; Dako) and
FITC-conjugated goat anti-rabbit IgG Ab (Zymed Laboratories)
was performed. To avoid cross-reaction of secondary antibodies,
sections were treated with nonimmunized goat IgG and sheep
IgG Fab fragment before incubation with FITC-conjugated goat
anti–rabbit IgG Ab.
The absence of primary Abs or digoxigenin-labeled dUTP
served as negative controls for these combinational staining meth-
ods. Sections were then covered with VECTASHIELD
 
®
 
 (Vector
Laboratories) and examined under a Carl Zeiss LSM 310 or a
Leica TCS NT confocal laser scanning microscope. Single beams
(488 nm for FITC, 542 nm for TRITC, and 600 nm for Cy5)
from an argon–krypton laser were used for excitation. Emissions
from FITC were detected through a long pass filter (
 
,
 
540 nm)
and displayed in green. Emissions from TRITC were detected
through a band pass filter (600 
 
6 
 
10 nm) and displayed in red.
Emissions from Cy5 were detected through a band pass filter
(740 
 
6 
 
70 nm) and displayed in blue or green.
 
Results
 
Reconstitution of Human Lymphoid Organ–like Structure in
the Spleens of hu-PBL-NOD-SCID Mice and Apoptosis in the
HIV-1–infected Spleen.
 
Splenomegaly was consistently ob-
served in the hu-PBL-NOD-SCID mice, reaching a maxi-
mum size within 2 wk that was three to five times larger
than the spleens of NOD-SCID mice (data not shown).
This splenomegaly was maintained up to 4–5 wk after trans-
plantation. Immunostaining of spleen sections with Abs spe-
cific for human leukocyte surface markers revealed that
many human CD3
 
1
 
 T cells, including both CD4
 
1
 
 and
CD8
 
1
 
 T cells, human CD20
 
1
 
 B cells, and a few human
CD68
 
1
 
 macrophages, efficiently migrated to the spleen from
 
the peritoneal cavity (data not shown). Human CD20
 
1
 
 B
cells were distributed close to the small arteries within 2–4
wk. Human CD3
 
1
 
 T cells were found in the periarterial re-
gion within 2 wk of transplantation and subsequently spread
to the region distal to the small arteries by 4 wk. Among the
CD3
 
1
 
 T cells, CD4
 
1
 
 T cells were found predominantly in
the proximal area, whereas CD8
 
1
 
 T cells were generally
found in the distal area. In the CD8
 
1
 
 T cell–rich regions,
scattered human CD68
 
1
 
 macrophages and human CD1a
 
1
 
DCs were found. In the spleens of untransplanted NOD-
SCID mice, no specific immunostaining was found.
A similar extent of splenomegaly was observed in HIV-
1–infected mice 2 wk after human PBL transplantation.
However, the splenomegaly in infected mice regressed
more rapidly than that of uninfected mice at 4 wk (data not
shown). A marked decrease in the number of human
CD4
 
1
 
 T cells was observed in infected mice with immu-
nostaining analysis (data not shown). HIV-1 p24
 
gag
 
–expres-
sing cells were found in the human CD4
 
1
 
 T cell–rich re-
gion; however, the number of p24
 
gag
 
1
 
 cells was far lower
than the number of human CD4
 
1
 
 T cells. In contrast, the
number and distribution of human CD8
 
1
 
 T cells, human
CD20
 
1
 
 B cells, and human CD68
 
1
 
 macrophages was ap-
parently unchanged. TUNEL staining showed a large
number of apoptotic cells around the small arteries in the
spleen 2 wk after HIV-1 infection (Fig. 1 
 
a
 
). In contrast,
only a few TUNEL
 
1
 
 apoptotic cells were observed in the
spleens of uninfected hu-PBL-NOD-SCID mice at the
same time point (data not shown). Furthermore, a NOD-
SCID mouse section without human PBL transplantation
showed no staining. The specificity of the TUNEL staining
was confirmed as described in Materials and Methods.
 
Predominant Apoptosis of HIV-1–uninfected Human CD4
 
1
 
T Cells.
 
To determine whether only HIV-1–infected cells
undergo apoptosis, multicolor immunostaining using Abs
against various molecules was employed together with the
TUNEL method. Triple-color staining for TUNEL, CD4,
and p24
 
gag
 
 showed that 
 
.
 
90% of the TUNEL
 
1
 
 apoptotic
cells in the spleen were human CD4
 
1
 
 cells 9 d after infec-
tion (Fig. 1 
 
a
 
). Furthermore, the majority of the apoptotic
CD4
 
1
 
 cells did not express detectable levels of p24. To
confirm the apoptosis of HIV-1–negative cells, hu-PBL-
NOD-SCID mice were inoculated with GFP-expressing
recombinant HIV-1, and their spleens were examined 9 d
after infection. As shown in Fig. 1 
 
b
 
, almost all TUNEL
 
1
 
apoptotic cells were GFP
 
2
 
. These results suggested that the
abundant depletion of human CD4
 
1
 
 T cells in the spleens
of HIV-1–infected hu-PBL-NOD-SCID mice was mostly
due to apoptosis of HIV-1–uninfected CD4
 
1
 
 T cells.
 
Critical Contribution of TRAIL to Human CD4
 
1
 
 T
Cell Apoptosis.
 
To explore the possible involvement of
TRAIL, FasL, and TNF-
 
a
 
 in human CD4
 
1
 
 T cell apopto-
sis in the spleens of HIV-1–infected hu-PBL-NOD-SCID
mice, we examined the expression of these death-inducing
ligands and their receptors by multicolor immunostaining
along with TUNEL staining. Since tissue slices were 10
 
m
 
m thick, a depth of only one to two cells was anticipated
in each section, thus enabling the identification of ligand- 
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positive cells conjugated with TUNEL
 
1
 
 apoptotic cells.
Strikingly, dual color staining for TRAIL and TUNEL
showed that 
 
.
 
50% of apoptotic cells were conjugated with
TRAIL
 
1
 
 cells (Fig. 2, 
 
a
 
 and 
 
g
 
). These TUNEL
 
1
 
 cell–con-
jugated TRAIL1 cells were human CD31CD41 T cells re-
vealed by triple staining of TUNEL, TRAIL, and either
CD4 or CD3 (Fig. 2, d–f). Similar results were obtained by
staining with anti–human TRAIL mAb RIK-2. Only a few
TRAIL1 cells were observed in the spleens of uninfected
mice (data not shown). In contrast, ,15% of TUNEL1 ap-
optotic cells were conjugated with FasL1 or TNF-a1 cells
(Fig. 2, b, c, and g). These findings suggested that TRAIL
might play a major role in human CD41 T cell apoptosis.
To further determine the contribution of TRAIL or FasL
to apoptosis of CD41 T cells, we administered neutralizing
anti-TRAIL or anti-FasL mAb to HIV-1–infected hu-
PBL-NOD-SCID mice 9 d after infection and counted
TUNEL1 cells in the spleen 3 d later. The number of
TUNEL1 apoptotic cells in anti-TRAIL mAb–treated mice
was markedly decreased as compared with the number in
untreated or control IgG–treated mice (Fig. 3 and Table I).
In contrast, no significant difference was observed between
Figure 1. Apoptosis occurs predominantly in HIV-1–uninfected
CD41 T cells. (a) Triple immunofluorescent staining for HIV p24gag
(FITC, green), human CD4 (Cy5, blue), and TUNEL (TRITC, red) of
spleens from HIV-1–infected hu-PBL-NOD-SCID mice 2 wk after in-
oculation of human PBMCs (9 d after infection). Original magnification
325 (left panel), 3100 (middle panel), and 31,000 (right two panels).
TUNEL (red) and CD4 (blue) double-positive cells are shown as pink in
lower magnification (left panel). CD4 (blue) and HIV p24gag (green) dou-
ble-positive cells are shown as light green. Arrow shows a small artery.
Right upper panel indicates TUNEL1, CD41, and p24gag1 cells, which
represented ,2% of both TUNEL1 and CD41 cells. Right lower panel
indicates TUNEL1, CD41, and p24gag2 cells, which accounted for .90%
of both TUNEL1 and CD41 cells. (b) Dual color detection for GFP-
expressing HIV-1 (GFP, green) and TUNEL staining (TRITC, red) of
spleens from GFP/HIV-1–infected hu-PBL-NOD-SCID mice 2 wk after
human PBL transplantation (9 d after infection). The majority of
TUNEL1 cells were GFP/HIV-1 negative. Original magnification 3100.655 Miura et al. Brief Definitive Report
anti-FasL mAb–treated mice and control IgG–treated mice.
These results indicated that TRAIL played a critical role in
the apoptotic depletion of human CD41 T cells in the
spleens of HIV-1–infected hu-PBL-NOD-SCID mice.
Discussion
The mechanism of CD41 T cell depletion in HIV-1–
infected individuals has not been fully elucidated (29). Our
study demonstrated that massive apoptosis of HIV-1–unin-
fected human CD41 T cells in the spleens of HIV-1–
infected hu-PBL-NOD-SCID mice was mainly mediated
by TRAIL expressed on adjacent human CD31CD41
T cells. As apoptotic depletion of HIV-uninfected CD41
T cells has also been observed in lymph nodes of HIV-1–
infected humans (3), a similar mechanism may be operative
in the pathogenesis of AIDS.
An unresolved issue critical for understanding the CD41
T cell depletion in HIV-1–infected individuals is that the
number of HIV-1–infected cells in vivo is significantly low.
Figure 2. Immunofluorescent analysis for death-inducing ligands and their receptors in spleens
from HIV-1–infected hu-PBL-NOD-SCID mice. (a) Double staining for TRAIL (Cy5, green) and
TUNEL (TRITC, red) (magnification 350). (b) Triple staining for FasL (FITC, green), TUNEL
(TRITC, red), and Fas (Cy5, blue) (magnification 350). (c) Triple staining for TNF-a (FITC,
green), TUNEL (TRITC, red), and TNFR1 (Cy5, blue) (magnification 350). (d) Triple staining
for human CD4 (FITC, green), TUNEL (TRITC, red), and TRAIL (Cy5, blue) (magnification
3100). Merging of green and blue is shown as light blue. Merging of green and red is shown as or-
ange. (e) High magnification (3500) of d showing a TUNEL1CD41 T cell conjugated with a
TRAIL1CD41 T cell (blue). Light blue indicates merging of green and blue. (f) Triple immu-
nostaining for human CD3 (FITC, green), TUNEL (TRITC, red), and TRAIL (Cy5, blue) (magni-
fication 3200). Merging of green and blue is shown as light blue. Merging of green and red is
shown as orange. (g) Quantification of TUNEL1 cells conjugated with death-inducing ligand–pos-
itive cells. TUNEL1 cells conjugated with TRAIL1, FasL1, or TNF-a1 cells (indicated by arrows
in a, b, and c) were counted in five randomly selected visual fields at magnification of 100. Data are
expressed as percentage of conjugates among total TUNEL1 cells (mean 6 SD of five fields).656 TRAIL-induced CD41 T Cell Apoptosis in HIV-infected hu-PBL-NOD-SCID Mice
Previous studies using quantitative PCR analysis have esti-
mated the presence of only one provirus-positive cell
among 1,000–20,000 PBLs from HIV-1–infected individu-
als (30). One reason for the low number of infected cells
and severe CD41 T cell depletion may be the rapid dy-
namics of HIV-1 replication in infected individuals, in
which productively HIV-1–infected CD41 T cells have a
very short half-life and z2 3 109 cells die per day (31, 32).
In addition, it has been postulated that HIV-1 infection
strongly forces uninfected CD41 T cells to die, and a by-
stander cell killing mechanism has been suggested by histo-
pathological analyses of lymph nodes obtained from HIV-
1–infected individuals and SIV-infected monkeys (3).
However, the molecular processes of this bystander mecha-
nism are controversial.
It has been reported that peripheral blood CD41 and
CD81 T cells from HIV-1–infected individuals were
highly susceptible to Fas-mediated apoptosis (6, 7). More-
over, in vitro exposure of monocytes to HIV-1 has been
reported to enhance FasL expression (33, 34). However,
subsequent studies showed that biological activity of FasL
was deficient in freshly isolated PBMCs from HIV-1–
infected individuals (11). In this study, we observed sub-
stantial numbers of both Fas1 and FasL1 cells in the spleens
of HIV-1–infected hu-PBL-NOD-SCID mice, but only a
few of these were associated with apoptotic cells (Fig. 2 b).
More importantly, administration of neutralizing anti-FasL
mAb did not significantly inhibit CD41 T cell apoptosis
(Fig. 3 and Table I). Thus, in our model, FasL was not the
principal mediator of the apoptosis.
Based on our findings, it is likely that TRAIL is prima-
rily responsible for apoptosis of bystander CD41 T cells in
HIV-infected lymphoid organs. There remain several issues
to be resolved in further studies. First, the mechanism by
which HIV-1 infection induces TRAIL expression in
CD31CD41 T cells remains to be determined. In this
study, we found that the number of TRAIL1 cells was
consistently higher in HIV-1–infected mice than in unin-
Figure 3. Inhibition of apoptosis by anti-TRAIL mAb. HIV-1–infected hu-PBL-NOD-SCID mice were injected intraperitoneally with 1 mg of anti-
TRAIL mAb (a), anti-FasL mAb (b), or control mouse IgG (c) 9 d after infection. After 3 d (12 d after infection), spleen sections were stained for apop-
totic cells by TUNEL (TRITC, red). Original magnification 3100.
Table I. Quantification of TUNEL1 Cells in the Spleens of 
HIV-1–infected hu-PBL-NOD-SCID Mice after Treatment with 
Anti–Human TRAIL mAb or Anti–Human FasL mAb
Mouse Donor Treatment No. TUNEL1 cells*
R1 S RIK-2‡ 42.4 6 11.2
R2 S RIK-2 19 6 3.86
R3 S RIK-2 17.6 6 4.01
R4 S RIK-2 23.8 6 8.22
R5 A RIK-2 35.7 6 10.8
R6 W RIK-2 27.2 6 3.71
R7 W RIK-2 26.3 6 4.88
R8 W RIK-2 32.5 6 3.87
R9 W RIK-2 35.2 6 9.89
N1 S NOK-1§ 65.9 6 14.5
N2 S NOK-1 80.9 6 8.74
N3 A NOK-1 65.1 6 10.5
N4 A NOK-1 70.6 6 9.96
N5 A NOK-1 63.7 6 9.76
N6 W NOK-1 77.8 6 12.8
N7 W NOK-1 83.1 6 14.7
N8 W NOK-1 62.2 6 14.3
IG1 S Control IgG 78.4 6 10
IG2 S Control IgG 72.3 6 9.18
IN1 A None 81.4 6 10.2
IN2 A None 89.9 6 15.8
*TUNEL1 cells were counted in 10 random visual fields at a magnifi-
cation of 100 and are indicated as mean 6 SD of 10 fields.
‡Anti–human TRAIL mAb.
§Anti–human FasL mAb.657 Miura et al. Brief Definitive Report
fected mice. It has been shown that the expression of
TRAIL on T cells was induced by a variety of stimuli, in-
cluding type I IFNs and TCR-mediated signals (13, 35,
36). Thus, it can be postulated that TRAIL was induced on
HIV-1–uninfected CD41 T cells either by viral or cellular
factors produced from HIV-1–infected or uninfected cells
in HIV-1–infected lymphoid organs. Second, it is necessary
to determine the exact receptor involved in TRAIL-medi-
ated apoptosis. TRAIL has been shown to interact with at
least four cell surface receptors on target cells, including
two death-inducing receptors (DR4 and DR5) and two
decoy receptors (DcR1 and DcR2) (37, 38). It has been
suggested that the expression of decoy receptors may be re-
sponsible for the protection of normal cells from TRAIL-
mediated apoptosis (37, 39). Therefore, certain factor(s)
arising from the virus-infected cells might upregulate the
expression of death receptors or downregulate the expres-
sion of decoy receptors on uninfected human CD41 T
cells. In addition, certain intracellular mechanism(s) that
regulate TRAIL-induced apoptosis, such as the expression
of cFLIP (cellular FLICE-inhibitory protein), might also be
affected (40). Further studies are necessary to address these
questions.
Some experimental advantages were recognized in the
hu-PBL-NOD-SCID mouse model of HIV infection used
in this study. First, a lymphoid organ–like structure could
be reconstituted in the spleens of NOD-SCID mice by
CD41 T cells, CD81 T cells, B cells, macrophages, and
DCs of human origin. Second, massive apoptosis of by-
stander CD41 T cells could be reproduced in the spleen af-
ter systemic HIV-1 infection. Indeed, this model was ap-
propriate for better analysis of apoptotic events, probably
due to macrophage dysfunction in NOD-SCID mice (41).
As apoptotic cells are rapidly eliminated by phagocytic
function of macrophages in normal animals (42), it is gen-
erally difficult to quantify the number of apoptotic cells in
vivo by histological methods. As the NOD-SCID mouse
has a low level of phagocyte activity, we were able to find
many TUNEL1 cells in hu-PBL-NOD-SCID mice.
Third, the hu-PBL-NOD-SCID mouse system was suit-
able for immunohistological analysis of human cells with
mouse-derived mAb because of the lack of endogenous
mouse Igs. Furthermore, Fc receptor–positive cells in
NOD mice have a low affinity for mouse IgG (43), result-
ing in little nonspecific staining. Finally, the possible con-
tribution of various molecules of interest could be easily
tested by the administration of neutralizing mAbs. These
advantages of the hu-PBL-NOD-SCID mouse model of
HIV-1 infection will aid further elucidation of the mecha-
nisms of CD41 T cell depletion by HIV-1 infection in in-
fected individuals.
In conclusion, this study has shown that TRAIL-medi-
ated apoptosis is the major mechanism of human CD41 T
cell destruction in the spleens of hu-PBL-NOD-SCID
mice after HIV-1 infection. Although this mechanism may
not fully account for the loss of CD41 T cells in HIV-1–
infected humans, TRAIL may be a significant target for
preventing the progression to AIDS.
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